Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 3interventionalRules rewrite

Phase 3: testing EB-1020 (Centanafadine) 164.4 mg for Attention Deficit Hyperactivity Disorder (ADHD)

This study wants to measure the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the neither you nor the study doctors know who gets the real treatment trial (405-102-00112) conducted in Japan

Official registry: https://clinicaltrials.gov/study/NCT06926829 · Otsuka Pharmaceutical Co., Ltd. · enrollment listed as 180

What this phase means

Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are EB-1020 (Centanafadine) 164.4 mg, or EB-1020 (Centanafadine) 328.8 mg. The registry lists allocation as randomized. This study wants to measure the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the neither you nor the study doctors know who gets the real treatment trial (405-102-00112) conducted in Japan

They plan to enroll about 180 people at Tokyo. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Trial to Evaluate the Safety and Efficacy of Long-term Administration of EB-1020 Once Daily QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder

Interventions: EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg

Primary outcome (registry wording): Number of Patients Experiencing Treatment-Emergent Adverse Events (TEAEs)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 55 Years
  • Participants who completed the treatment period andfollow-up period in the preceding neither you nor the study doctors know who gets the real treatment parent Trial (Trial 405-102-00112) and did not meet the criteria for discontinuation of the investigational medicinal product (IMP)
  • Participants who have not been found to have major problems with trial requirements, such as compliance with the IMP, in the preceding neither you nor the study doctors know who gets the real treatment parent trial

Public study contact (from the registry)

Drug Information Center

+81-3-6361-7314

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBoston, Massachusetts
National Pregnancy Registry for Psychiatric Medications

The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.

NCT01246765 · Official ClinicalTrials.gov record · Massachusetts General Hospital

RecruitingNot a traditional drug phaseSacramento, California
Not a traditional drug phase: VR Treatment for ADHD

Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to distraction is associated with worse school and social performance, lower high school graduation rates, and increased incidence of serious accidents.

NCT03221244 · Official ClinicalTrials.gov record · University of California, Davis

RecruitingNot a traditional drug phasePhoenix, Arizona
Not a traditional drug phase: testing The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: for Coronavirus Infection (COVID-19)

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to measure the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

NCT04278404 · Official ClinicalTrials.gov record · Duke University

FAQ about this NCT record

Is NCT06926829 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06926829?

Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06926829?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary